Since Aptevo Therapeutics Inc. (NASDAQ:APVO) and Intellia Therapeutics Inc. (NASDAQ:NTLA) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation of both companies.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics Inc.	19.54M	1.84	49.36M	-2.21	0.00
Intellia Therapeutics Inc.	30.43M	24.65	85.34M	-2.16	0.00

Table 1 highlights Aptevo Therapeutics Inc. and Intellia Therapeutics Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows Aptevo Therapeutics Inc. and Intellia Therapeutics Inc.’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics Inc.	-252.61%	-78.8%	-51.1%
Intellia Therapeutics Inc.	-280.45%	-30.6%	-25%

Liquidity

The Current Ratio of Aptevo Therapeutics Inc. is 3.9 while its Quick Ratio stands at 3.7. The Current Ratio of rival Intellia Therapeutics Inc. is 8 and its Quick Ratio is has 8. Intellia Therapeutics Inc. is better equipped to clear short and long-term obligations than Aptevo Therapeutics Inc.

Institutional & Insider Ownership

Aptevo Therapeutics Inc. and Intellia Therapeutics Inc. has shares held by institutional investors as follows: 32.2% and 74.6%. Insiders held 1% of Aptevo Therapeutics Inc. shares. Insiders Competitively, held 24.01% of Intellia Therapeutics Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Aptevo Therapeutics Inc.	-12.8%	-10.63%	-37%	-72.97%	-52.96%	12.6%
Intellia Therapeutics Inc.	15.53%	17.33%	-2.93%	-44.98%	-34.45%	21.54%

For the past year Aptevo Therapeutics Inc. has weaker performance than Intellia Therapeutics Inc.

Summary

Intellia Therapeutics Inc. beats Aptevo Therapeutics Inc. on 7 of the 10 factors.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. Intellia Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.